PL3512506T3 - Zastosowanie pridopidyny w leczeniu zespołu retta - Google Patents
Zastosowanie pridopidyny w leczeniu zespołu rettaInfo
- Publication number
- PL3512506T3 PL3512506T3 PL17851614T PL17851614T PL3512506T3 PL 3512506 T3 PL3512506 T3 PL 3512506T3 PL 17851614 T PL17851614 T PL 17851614T PL 17851614 T PL17851614 T PL 17851614T PL 3512506 T3 PL3512506 T3 PL 3512506T3
- Authority
- PL
- Poland
- Prior art keywords
- pridopidine
- rett syndrome
- treating rett
- treating
- syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395854P | 2016-09-16 | 2016-09-16 | |
| EP17851614.2A EP3512506B1 (en) | 2016-09-16 | 2017-09-15 | Use of pridopidine for treating rett syndrome |
| PCT/US2017/051803 WO2018053280A1 (en) | 2016-09-16 | 2017-09-15 | Use of pridopidine for treating rett syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3512506T3 true PL3512506T3 (pl) | 2022-05-30 |
Family
ID=61619744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17851614T PL3512506T3 (pl) | 2016-09-16 | 2017-09-15 | Zastosowanie pridopidyny w leczeniu zespołu retta |
| PL22150695.9T PL4005570T3 (pl) | 2016-09-16 | 2017-09-15 | Pridopidyna do zastosowania w leczeniu zespołu retta |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22150695.9T PL4005570T3 (pl) | 2016-09-16 | 2017-09-15 | Pridopidyna do zastosowania w leczeniu zespołu retta |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP3512506B1 (pl) |
| JP (1) | JP6977029B2 (pl) |
| CN (1) | CN109982686A (pl) |
| AU (1) | AU2017326013B2 (pl) |
| BR (1) | BR112019005040A2 (pl) |
| CA (1) | CA3036984C (pl) |
| DK (2) | DK3512506T3 (pl) |
| ES (1) | ES2909557T3 (pl) |
| HU (1) | HUE058314T2 (pl) |
| IL (1) | IL265342B2 (pl) |
| MX (1) | MX2019003069A (pl) |
| PL (2) | PL3512506T3 (pl) |
| WO (1) | WO2018053280A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3010506T3 (pl) | 2013-06-21 | 2021-11-02 | Prilenia Neurotherapeutics Ltd. | Pridopidyna w leczeniu choroby huntingtona |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| EP3503890A4 (en) | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA |
| US11207310B2 (en) | 2016-08-24 | 2021-12-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| JP6977029B2 (ja) | 2016-09-16 | 2021-12-08 | プリレニア ニューロセラピューティクス リミテッド | レット症候群を治療するためのプリドピジンの使用 |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| HUE029790T2 (hu) | 2004-10-13 | 2017-04-28 | Teva Pharmaceuticals Int Gmbh | Eljárás 4-(3-metánszulfonil-fenil)-l-N-propil-piperidin elõállítására |
| AU2011298382A1 (en) | 2010-09-03 | 2013-05-02 | Teva Pharmaceuticals International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| JP6177875B2 (ja) | 2012-04-04 | 2017-08-09 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 併用療法のための医薬組成物 |
| PL3010506T3 (pl) | 2013-06-21 | 2021-11-02 | Prilenia Neurotherapeutics Ltd. | Pridopidyna w leczeniu choroby huntingtona |
| JP6949487B2 (ja) | 2014-01-22 | 2021-10-13 | プリレニア・ニューロセラピューティクス・エルティーディーＰｒｉｌｅｎｉａ Ｎｅｕｒｏｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ | プリドピジンの調節放出製剤 |
| WO2016138135A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| PL3261721T3 (pl) * | 2015-02-25 | 2022-12-27 | Prilenia Neurotherapeutics Ltd. | Stososowanie pridopidyny w celu poprawy pamięci |
| JP6977029B2 (ja) | 2016-09-16 | 2021-12-08 | プリレニア ニューロセラピューティクス リミテッド | レット症候群を治療するためのプリドピジンの使用 |
-
2017
- 2017-09-15 JP JP2019514217A patent/JP6977029B2/ja active Active
- 2017-09-15 HU HUE17851614A patent/HUE058314T2/hu unknown
- 2017-09-15 PL PL17851614T patent/PL3512506T3/pl unknown
- 2017-09-15 EP EP17851614.2A patent/EP3512506B1/en active Active
- 2017-09-15 DK DK17851614.2T patent/DK3512506T3/da active
- 2017-09-15 EP EP22150695.9A patent/EP4005570B1/en active Active
- 2017-09-15 DK DK22150695.9T patent/DK4005570T3/da active
- 2017-09-15 MX MX2019003069A patent/MX2019003069A/es unknown
- 2017-09-15 AU AU2017326013A patent/AU2017326013B2/en active Active
- 2017-09-15 CN CN201780071045.XA patent/CN109982686A/zh active Pending
- 2017-09-15 PL PL22150695.9T patent/PL4005570T3/pl unknown
- 2017-09-15 BR BR112019005040A patent/BR112019005040A2/pt not_active Application Discontinuation
- 2017-09-15 ES ES17851614T patent/ES2909557T3/es active Active
- 2017-09-15 WO PCT/US2017/051803 patent/WO2018053280A1/en unknown
- 2017-09-15 CA CA3036984A patent/CA3036984C/en active Active
-
2019
- 2019-03-13 IL IL265342A patent/IL265342B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019005040A2 (pt) | 2019-07-16 |
| CA3036984C (en) | 2023-07-18 |
| HUE058314T2 (hu) | 2022-07-28 |
| ES2909557T3 (es) | 2022-05-09 |
| JP2019532926A (ja) | 2019-11-14 |
| AU2017326013A1 (en) | 2019-04-11 |
| CN109982686A (zh) | 2019-07-05 |
| CA3036984A1 (en) | 2018-03-22 |
| AU2017326013B2 (en) | 2020-12-24 |
| DK3512506T3 (da) | 2022-04-19 |
| EP4005570B1 (en) | 2024-05-15 |
| IL265342A (en) | 2019-05-30 |
| EP3512506A4 (en) | 2020-05-27 |
| PL4005570T3 (pl) | 2024-09-23 |
| EP3512506B1 (en) | 2022-01-26 |
| MX2019003069A (es) | 2019-09-02 |
| EP4005570A1 (en) | 2022-06-01 |
| JP6977029B2 (ja) | 2021-12-08 |
| DK4005570T3 (da) | 2024-08-19 |
| IL265342B2 (en) | 2023-06-01 |
| WO2018053280A1 (en) | 2018-03-22 |
| EP3512506A1 (en) | 2019-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181661T1 (hr) | Inhibitori jak1 za liječenje mijelodisplastičnih sindroma | |
| IL251584A0 (en) | Dihydropyrrolopyridines ror-gamma inhibitors | |
| IL246902B (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
| HK1232147A1 (zh) | 用於治療纖維化的賽尼克韋羅 | |
| IL265342A (en) | Use of pridofidine for the treatment of Rett syndrome | |
| ZA201706257B (en) | Treatment of wood | |
| IL257061A (en) | Inhibitors of ezh2 | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL259856A (en) | A preparation for the treatment of Crigler-Najjar syndrome | |
| PL3122349T3 (pl) | Kompozycje do leczenia samotrawienia | |
| IL251350A0 (en) | Treatment of Rett syndrome | |
| IL262547A (en) | Methods and compositions for treatment of rett syndrome | |
| EP3122187A4 (en) | Treatment of rett syndrome |